Genetic Background and Clinicopathologic Features Established for Adult-Onset Nephronophthisis
|
By LabMedica International staff writers Posted on 06 May 2021 |

Image: The Hamamatsu Photonics Nanozoomer 1 Digital Slide Scanner (Photo courtesy of University of Adelaide)
Nephronophthisis (NPH) is a genetic disorder of the kidneys which mainly affects children. It is classified as a medullary cystic kidney disease. The disorder is inherited in an autosomal recessive fashion and, although rare, is the most common genetic cause of childhood kidney failure.
Even in adult patients, accurate diagnosis of NPH is important because management options, such as kidney transplantation and appropriate genetic counseling, are available. The clinical diagnosis of adult NPH is problematic because clinical, radiologic and histologic features are non-specific. Even the extrarenal features are fewer in adults. Because management includes renal transplantation and genetic counseling, an accurate early diagnosis is essential.
Nephrologists at the Tokyo Medical and Dental University (Tokyo, Japan) investigated 18 adult patients who were suspected to have NPH by renal biopsy. The patients were recruited at 16 institutions in Japan between 2015 and 2019. For each patient, the tissue slides that were stained with hematoxylin-eosin, periodic acid-Schiff, and periodic acid–methenamine silver were digitized using the NanoZoomer HT Scan system (Hamamatsu Photonics, Hamamatsu, Japan).
Comprehensive genetic testing was performed using capture-based next-generation sequencing of 69 genes that cause nine types of hereditary cystic kidney disease, including NPH, NPH-related ciliopathies (Joubert syndrome, Meckel syndrome, Senior-Løken syndrome, Bardet-Biedl syndrome, and skeletal ciliopathies), autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney disease, and autosomal dominant tubulointerstitial kidney disease.
The scientists performed polymerase chain reaction for exons 1, 10, and 20 of NPHP1, if homozygous entire deletion of NPHP1 was detected by copy number variation analysis. To investigate what the essence of thick tubular basement membrane (TBM) duplication was, they performed low-vacuum scanning electron microscopic (Hitachi, Tokyo, Japan) analysis and immunofluorescence (IF) analysis in the representative cases with or without pathogenic mutations.
The investigators reported that seven of 18 patients had pathogenic NPH-causing mutations in NPHP1, NPHP3, NPHP4, or CEP164. Compared with patients without pathogenic mutations, those with pathogenic mutations were significantly younger, but did not significantly differ in the classic NPH pathologic findings, such as tubular cysts. On the other hand, the number of tubules with thick TBM duplication, which was defined as >10-μm thickness, was significantly higher in patients with genetically proven adult NPH than in those without pathogenic mutations. α-Smooth muscle actin (α-SMA)-positive myofibroblasts were detected inside thick TBM duplication.
The authors concluded that in adult patients with NPH, thick TBM duplication was the specific finding. Their analysis also suggested that older patients tended to have no pathogenic mutations, even when they were suspected to have NPH by renal biopsy. These findings could be the novel clinical clue for the diagnosis of NPH in adult patients. The study was published originally on March 3, 2021 in the journal Kidney International Reports.
Related Links:
Tokyo Medical and Dental University
Hamamatsu Photonics
Hitachi
Even in adult patients, accurate diagnosis of NPH is important because management options, such as kidney transplantation and appropriate genetic counseling, are available. The clinical diagnosis of adult NPH is problematic because clinical, radiologic and histologic features are non-specific. Even the extrarenal features are fewer in adults. Because management includes renal transplantation and genetic counseling, an accurate early diagnosis is essential.
Nephrologists at the Tokyo Medical and Dental University (Tokyo, Japan) investigated 18 adult patients who were suspected to have NPH by renal biopsy. The patients were recruited at 16 institutions in Japan between 2015 and 2019. For each patient, the tissue slides that were stained with hematoxylin-eosin, periodic acid-Schiff, and periodic acid–methenamine silver were digitized using the NanoZoomer HT Scan system (Hamamatsu Photonics, Hamamatsu, Japan).
Comprehensive genetic testing was performed using capture-based next-generation sequencing of 69 genes that cause nine types of hereditary cystic kidney disease, including NPH, NPH-related ciliopathies (Joubert syndrome, Meckel syndrome, Senior-Løken syndrome, Bardet-Biedl syndrome, and skeletal ciliopathies), autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney disease, and autosomal dominant tubulointerstitial kidney disease.
The scientists performed polymerase chain reaction for exons 1, 10, and 20 of NPHP1, if homozygous entire deletion of NPHP1 was detected by copy number variation analysis. To investigate what the essence of thick tubular basement membrane (TBM) duplication was, they performed low-vacuum scanning electron microscopic (Hitachi, Tokyo, Japan) analysis and immunofluorescence (IF) analysis in the representative cases with or without pathogenic mutations.
The investigators reported that seven of 18 patients had pathogenic NPH-causing mutations in NPHP1, NPHP3, NPHP4, or CEP164. Compared with patients without pathogenic mutations, those with pathogenic mutations were significantly younger, but did not significantly differ in the classic NPH pathologic findings, such as tubular cysts. On the other hand, the number of tubules with thick TBM duplication, which was defined as >10-μm thickness, was significantly higher in patients with genetically proven adult NPH than in those without pathogenic mutations. α-Smooth muscle actin (α-SMA)-positive myofibroblasts were detected inside thick TBM duplication.
The authors concluded that in adult patients with NPH, thick TBM duplication was the specific finding. Their analysis also suggested that older patients tended to have no pathogenic mutations, even when they were suspected to have NPH by renal biopsy. These findings could be the novel clinical clue for the diagnosis of NPH in adult patients. The study was published originally on March 3, 2021 in the journal Kidney International Reports.
Related Links:
Tokyo Medical and Dental University
Hamamatsu Photonics
Hitachi
Latest Pathology News
- Blood-Based Method Tracks Gene Activity in the Living Brain
- FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors
- AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
- AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
- Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
- AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
- FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
- New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
- AI System Analyzes Routine Pathology Slides to Predict Cancer Outcomes
- New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease
- Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
- Interpretable AI Reveals Hidden Cellular Features from Microscopy Images
- Tumor Immune Structure Predicts Response to Immunotherapy in Melanoma
- Plug-and-Play AI Pathology System Classifies Multiple Cancers from Few Slides
- AI-Based Assays Support Risk Stratification in Prostate and Breast Cancer
- AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
Channels
Clinical Chemistry
view channel
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Genomic Test Guides Chemotherapy Decisions in Early-Stage Breast Cancer
Selecting adjuvant therapy for early-stage hormone receptor-positive breast cancer depends on accurately assessing long-term risk of distant recurrence. Clinical features alone can leave uncertainty about... Read more
Simple Cytogenetic Method Could Improve Classification of ALL Subtypes
Many cancers deviate from the normal chromosome number, but the clinical impact of extreme chromosome loss remains unclear. This widespread genomic disruption is associated with aggressive disease and... Read more
Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
Sarcomas remain difficult to monitor during immunotherapy, as low tumor mutation burden can limit traditional circulating tumor DNA approaches and repeat tissue biopsies are often impractical in advanced disease.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








